-Net profit up 59.9 percent at Rs 175.9 crore versus Rs 110 crore (YoY)
-Total income down 6.2 percent at Rs 2,231 crore versus Rs 2,379.2 crore (YoY)
-EBITDA up 0.5 percent at Rs 329.1 crore versus Rs 327.6 crore (YoY)
-Net profit down 5.7 percent at Rs 23 crore versus Rs 24.4 crore (YoY)
-Total income up 3.1 percent at Rs 251.2 crore versus Rs 243.7 crore (YoY)
-EBITDA down 11.7 percent at Rs 36.2 crore versus Rs 41 crore (YoY)
-No outstanding items with US FDA w.r.t Ankleshwar plant
-Ankleshwar plant was inspected by US FDA in December and had got 4 observations
-Had responded to US FDA in January w.r.t observations for Ankleshwar unit
Get us on http://www.ripplesadvisory.com/aboutus.php click here, more and for Two days Free Trial drop your missed call on -9303093093
No comments:
Post a Comment